PMID- 17450185
OWN - NLM
STAT- MEDLINE
DCOM- 20070809
LR  - 20201226
IS  - 0268-3369 (Print)
IS  - 0268-3369 (Linking)
VI  - 39
IP  - 12
DP  - 2007 Jun
TI  - Long term disease-free survival in acute leukemia patients recovering with 
      increased gammadelta T cells after partially mismatched related donor bone marrow 
      transplantation.
PG  - 751-7
AB  - Allogeneic stem cell transplantation (ASCT) has improved leukemia-free survival 
      (LFS) in many but not all patients with acute leukemia. This is an eight-year 
      follow-up to our previous study showing a survival advantage to patients with an 
      increased gammadelta T cells following ASCT. gammadelta T cell levels were 
      collected prospectively in 153 patients (acute lymphoblastic leukemia (ALL) n = 
      77; acute myelogenous leukemia (AML) n = 76) undergoing partially mismatched 
      related donor ASCT. Median age was 22 years (1-59), and 62% of the patients were 
      in relapse at transplant. Patient-donor human leukocyte antigen (HLA) disparity 
      of three antigens was 37% in the graft-versus-host disease (GvHD) and 29% in the 
      rejection directions. All patients received a partially T cell-depleted graft 
      using T10B9 (n = 46) or OKT3 (n = 107). Five years LFS and overall survival (OS) 
      of patients with increased gammadelta compared to those with normal/decreased 
      numbers were 54.4 vs 19.1%; P < 0.0003, and 70.8 vs 19.6% P < 0.0001, 
      respectively, with no difference in GvHD (P = 0.96). In a Cox multivariate 
      analysis, normal/decreased gammadelta (hazard ratio (HR) 4.26, P = 0.0002) and 
      sex mismatch (HR 1.45 P=0.049) were associated with inferior LFS. In conclusion, 
      gammadelta T cells may facilitate a graft-versus-leukemia (GvL) effect, without 
      causing GvHD. Further evaluations of this effect may lead to specific 
      immunotherapy for patients with refractory leukemia.
FAU - Godder, K T
AU  - Godder KT
AD  - South Carolina Cancer Center, Columbia, SC, USA. kgodder@vcu.edu
FAU - Henslee-Downey, P J
AU  - Henslee-Downey PJ
FAU - Mehta, J
AU  - Mehta J
FAU - Park, B S
AU  - Park BS
FAU - Chiang, K-Y
AU  - Chiang KY
FAU - Abhyankar, S
AU  - Abhyankar S
FAU - Lamb, L S
AU  - Lamb LS
LA  - eng
GR  - R21 CA 76667/CA/NCI NIH HHS/United States
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20070423
PL  - England
TA  - Bone Marrow Transplant
JT  - Bone marrow transplantation
JID - 8702459
RN  - 0 (Receptors, Antigen, T-Cell, gamma-delta)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - *Bone Marrow Transplantation
MH  - Cause of Death
MH  - Child
MH  - Child, Preschool
MH  - Disease-Free Survival
MH  - Female
MH  - Follow-Up Studies
MH  - Graft vs Host Disease/mortality
MH  - *Histocompatibility Testing
MH  - Humans
MH  - Infant
MH  - Kaplan-Meier Estimate
MH  - Leukemia, Myeloid, Acute/mortality/*therapy
MH  - Male
MH  - Middle Aged
MH  - Precursor Cell Lymphoblastic Leukemia-Lymphoma/mortality/*therapy
MH  - Prospective Studies
MH  - Receptors, Antigen, T-Cell, gamma-delta/*metabolism
MH  - Recurrence
MH  - Tissue Donors
MH  - Transplantation, Homologous
EDAT- 2007/04/24 09:00
MHDA- 2007/08/10 09:00
CRDT- 2007/04/24 09:00
PHST- 2007/04/24 09:00 [pubmed]
PHST- 2007/08/10 09:00 [medline]
PHST- 2007/04/24 09:00 [entrez]
AID - 1705650 [pii]
AID - 10.1038/sj.bmt.1705650 [doi]
PST - ppublish
SO  - Bone Marrow Transplant. 2007 Jun;39(12):751-7. doi: 10.1038/sj.bmt.1705650. Epub 
      2007 Apr 23.